Drug Database
NI

NIK-127

✓ Approved

Kowa · Small Molecule · Small Molecule

What is NIK-127?

NIK-127 is a small molecule developed by Kowa. It is approved for therapeutic indications via unknown.

Drug Profile

CompanyKowa
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Kowa

Therapeutic Indications

NIK-127 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersDiarrhoea✓ Approved

Related Research Articles

PubMedMedicine2026-09-19

Multilevel factors predicting medication adherence among gout patients in China: A 1‑year prospective cohort study.

Jiang Haiyan H, Yang Yanda Y, Lei Xuan X, Yi Ting T et al.

Adherence to urate-lowering therapy (ULT) is crucial for gout management, yet it remains suboptimal worldwide, particularly in China where relevant data are scarce. This study investigates the prevalence and predictors of medication adherence among Chinese gout patients receiving ULT over a 1-year period. A 1-year prospective cohort study was conducted among gout patients prescribed ULT at a single center. Adherence was assessed using the Compliance Questionnaire in Rheumatology at 6 and 12 months, with scores ≥80% defining adherence. Predictors encompassing socioeconomic, therapy-related, patient-related, condition-related, and healthcare system-related factors were analyzed using multiple linear regression models. Among 141 recruited patients (96.5% male), the adherence prevalence was 8.3% (11/133) at 6 months and 7.1% (9/127) at 1 year. In multiple linear regression, a higher gout knowledge (Gout Knowledge Questionnaire) score was independently associated with better adherence at 6 months (β = -0.223, P = .001). At 1 year, taking urate-lowering agent in the past week was the sole independent predictor (β = 0.178, P = .014). Medication adherence to ULT among gout patients in this Chinese cohort is notably low and declines over time. Patient knowledge and recent medication-taking behavior are key modifiable predictors. Interventions should be targeted within the first 6 months of therapy.

PMID 42760678
Read full article →
PubMedBMJ health & care informatics2026-09-18

Applications of the Early Warning Score as an outcome measure: a systematic review of methodologies.

Griffin Katherine K, Ryan Jessica M JM, Sorensen Jan J, Labbe Laura L et al.

To evaluate how Early Warning Scores (EWS) are used and analysed as research outcome measures in interventional and comparative studies and to assess the consistency and methodological rigour of these approaches. We conducted a systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (INPLASY 202540054), searching OVID Medline (MEDLINE, Embase, CENTRAL) (1946 to 6 January 2026) for interventional or comparative studies using an EWS as a research outcome measure. Three reviewers independently screened articles, extracted data and performed a narrative synthesis of methodological approaches regarding the use and analysis of EWS as a research outcome. EWS were most commonly derived from intermittent ward observations (92/127, 72.0%) rather than continuous monitoring (2/127, 1.6%). Outcomes were typically defined as clinically interpretable summary measures, including index-time values, maximum scores within defined windows or threshold-based categories. Temporal analysis was limited, with most studies not incorporating time explicitly (91/127, 71.7%). Where time was considered (32/127, 25.2%), approaches focused on short-horizon prediction or fixed time point comparisons rather than modelling longitudinal trajectories; explicit assessment of change in EWS was uncommon (14/127, 11.0%). Reporting prioritised discrimination (98/127, 77.2%) over calibration (38/127, 29.9%), with variable consideration of repeated measures, missing data and validation. EWS are predominantly used as simple, clinically interpretable severity endpoints rather than as longitudinal measures of physiological change. Inconsistent handling of temporality and limited methodological standardisation restrict comparability and interpretation despite the availability of repeated time-stamped data. Development of reporting and analytic guidance is needed to support more robust use of EWS as research outcomes.

PMID 42759974
Read full article →
PubMedPostgraduate medical journal2026-09-18

Potential clinical utility of a KDIGO 2021-based clinical decision support system for glomerular diseases: a retrospective two-center pilot study.

Michalak Krzysztof K, Sędziak Oliwia O, Pawuś Dawid D, Benc Krzysztof K et al.

Glomerulopathies are a heterogeneous group of diseases characterized by complex immunopathogenesis and wide clinical variability. A wide range of laboratory and histopathological tests is used to assess glomerular diseases. However, the volume of data is often too great to analyze and to provide a clear diagnosis. The rapid development of artificial intelligence (AI) methodologies, including machine learning (ML) and deep learning, facilitates the integration of histopathological, clinical, and molecular data. This foundation enables the creation of more precise and objective diagnostic models. Modular expert systems based on ML algorithms (XGBoost, Random Forest, and natural language processing were implemented. A retrospective comparative analysis was performed comparing physician decisions with algorithmic recommendations in a patient cohort from the Opole University Clinical Hospital and the Wroclaw Medical University Hospital (2018-2025), comprising idiopathic membranous glomerulonephritis (iMN, n = 56), focal segmental glomerulosclerosis (FSGS, n = 127), lupus nephritis (LN, n = 31), and minimal change disease (MCD, n = 187). The iMN module achieved 100% accuracy in risk categorization. Retrospective analysis revealed significant gaps in clinical practice: 13.4% of decisions were suboptimal in the FSGS group, 25.8% of diagnoses were irregular in the LN cohort, and 10.8% of diagnoses were irregular in the MCD group. The integration of AI into clinical practice is a key element in the evolution of "precision nephrology," supporting the detection of subtle disease patterns and the standardization of management.

PMID 42758597
Read full article →
PubMedBMJ neurology open2026-09-18

From brain to heart: a single-centre study of ictal and post-ictal asystole in epilepsy.

Gohel Abhishek A, Philip Belinda B, Raman Akshaya A, Shah Rutul R et al.

The objective of this study is to explore ictal asystole (IA), a neurocardiogenic phenomenon occurring during epileptic seizures, and its implications in patients with epilepsy. The study aims to describe the clinical presentations, diagnostic challenges and management approaches of IA to contribute to the existing knowledge and improve patient care. A retrospective analysis was conducted on 15 578 patients undergoing prolonged video-electroencephalogram monitoring over a period of 115 months. Clinical features, electrophysiology, neuroimaging, interventions and outcomes were assessed. Eight patients (0.05%) exhibited IA (six females; mean age: 36.5 years; range: 26-45 years). The mean age at seizure onset was 20.5±11.73 years and mean disease duration from seizure onset was 16±10.66 years. Six patients gave a history of hypomotor features (75%), one exhibited automotor features (12.5%) and one exhibited sensorimotor features (12.5%). Of the 127 ictal events analysed, 47 (37%) progressed to asystole and 80 (63%) had bradycardia without asystole. Bradycardia preceded 95.7% of asystolic events. A significant direct correlation was observed between average duration of IA and average seizure duration (p=0.015). IA was predominantly observed in temporal lobe epilepsy. Falls and myoclonus were observed during asystolic events. All patients survived without requiring resuscitation. Six patients underwent surgical intervention for epilepsy, with varying degrees of success. One patient underwent permanent pacemaker implantation. Clinicians should consider IA in patients with epilepsy presenting with unexplained syncope or sudden falls, especially when associated with recent changes in seizure semiology. A high index of suspicion is essential to enable timely diagnosis and prevent injury.

PMID 42756505
Read full article →
PubMedFrontiers in global women's health2026-09-18

Personal sense of coherence and posttraumatic stress symptoms among internally displaced women exposed to the Anglophone Crisis in Cameroon.

Kouamen Tatto Mouandjo Edwige Emilie EE, Mbwayo Anne Wandjiru AW, Mathai Anne Muthoni AM, Fotso Djemo Jean-Baptiste JB et al.

Women and girls affected by armed conflict and forced displacement are exposed to a high burden of potentially traumatic events, gendered insecurity, disrupted social networks, and barriers to mental health care. Evidence on protective psychological resources among internally displaced women in Central Africa remains limited. This study examined trauma load, personal sense of coherence (SoC), and sense of community coherence (SoCC) as predictors of posttraumatic stress disorder (PTSD) symptom severity among women internally displaced by the Anglophone Crisis in Cameroon. A sample of 133 female internally displaced persons (IDPs), aged 18 to 65 years, was recruited from two humanitarian organizations. Trauma exposure was assessed using the Life Events Checklist for DSM-5 and a crisis-specific trauma checklist; PTSD symptom severity was measured with the PTSD Checklist for DSM-5; and SoC and SoCC were assessed with validated self-report scales. Among six trauma-load indicators, self-experienced traumatic event types related to the Anglophone Crisis were the only trauma-related predictor retained in the final regression model. The final model included self-experienced Anglophone Crisis-related trauma (β = .23, p = .009) and personal SoC (β = -.18, p = .035), F(2, 130) = 7.41, p < .001, adjusted R 2 = .09. Using the PCL-5 screening cut-off of 31, 127 of 133 women (95.5%) met the threshold for probable PTSD. The findings do not establish causal mediation, but they support the interpretation that individual comprehensibility, manageability, and meaningfulness are clinically relevant resilience-related resources for displaced women. Interventions for female IDPs should combine trauma-focused care with strategies that strengthen individual coping and meaning-making while acknowledging that displacement can disrupt community-level protection.

PMID 42755885
Read full article →
PubMedCJC open2026-09-18

Rationale and Design of the Canadian Lipoprotein(a) Registry.

Kramer Adam I AI, Abdel-Qadir Husam H, Abramson Beth L BL, Baass Alexis A et al.

Lipoprotein(a) [Lp(a)] is an independent, heritable risk factor for atherosclerotic cardiovascular disease. Guidelines recommend Lp(a) testing once in a lifetime and recognize it as a risk-enhancing factor. However, management of elevated Lp(a) in real-world clinical practice is not well described. Here we describe the rationale, design, and preliminary baseline characteristics of the Canadian Lp(a) Registry, a prospective, longitudinal observational study of patients with Lp(a) ≥ 100 nmol/L (≥ 50 mg/dL). Patient demographics, cardiovascular risk factors, laboratory results, and clinical outcomes are collected at baseline and at annual follow-up. The primary objective is to evaluate the clinical management and outcomes of patients with elevated Lp(a). From April 2024 to April 2025, 127 patients (mean age 57.5 ± 12.7 years, 48.8% female) were enrolled with a median Lp(a) level of 225 nmol/L (interquartile range 186-346 nmol/L), and 51.2% had multiple Lp(a) levels obtained. The most recent mean low-density lipoprotein cholesterol (LDL-C) was 2.49 ± 1.74 mmol/L. At the time of registry entry, 104 (81.9%) patients were receiving lipid-lowering therapies, including statins (74.8%), ezetimibe (48.0%), and proprotein convertase subtilisin/kexin type 9 inhibitors (27.6%), whereas 18.1% were not taking prescription lipid-lowering therapy. There were 66 (52.0%) patients with an LDL-C < 2.0 mmol/L. The Canadian Lp(a) Registry is an ongoing prospective, observational study designed to evaluate the clinical management, cardiovascular risk profile, and outcomes for patients with elevated Lp(a). It is expected to improve our understanding of how elevated Lp(a) is managed in contemporary clinical practice and to identify opportunities to improve care.

PMID 42756755
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about NIK-127